nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0211	0.0211	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0207	0.0207	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0205	0.0205	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.0186	0.0186	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0181	0.0181	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.0181	0.0181	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0177	0.0177	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0151	0.0151	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0148	0.0148	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0147	0.0147	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0143	0.0143	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.0138	0.0138	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0135	0.0135	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.013	0.013	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0127	0.0127	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0125	0.0125	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0123	0.0123	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.0118	0.0118	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0117	0.0117	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0116	0.0116	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.0113	0.0113	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0111	0.0111	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.011	0.011	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0107	0.0107	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0105	0.0105	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0103	0.0103	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0102	0.0102	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00999	0.00999	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00986	0.00986	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00967	0.00967	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00966	0.00966	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00951	0.00951	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00939	0.00939	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00936	0.00936	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00925	0.00925	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00897	0.00897	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0088	0.0088	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00875	0.00875	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00851	0.00851	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00834	0.00834	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00831	0.00831	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00827	0.00827	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00818	0.00818	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00808	0.00808	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00794	0.00794	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00784	0.00784	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00779	0.00779	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00769	0.00769	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00763	0.00763	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00761	0.00761	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00755	0.00755	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00755	0.00755	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00737	0.00737	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00731	0.00731	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00724	0.00724	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00715	0.00715	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00715	0.00715	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00715	0.00715	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00707	0.00707	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00693	0.00693	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00692	0.00692	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.0068	0.0068	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00672	0.00672	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0067	0.0067	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00666	0.00666	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00662	0.00662	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00626	0.00626	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00623	0.00623	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00613	0.00613	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00592	0.00592	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00585	0.00585	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00557	0.00557	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00546	0.00546	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00544	0.00544	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00529	0.00529	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00527	0.00527	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00518	0.00518	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00512	0.00512	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00512	0.00512	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00506	0.00506	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00496	0.00496	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00486	0.00486	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0048	0.0048	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00477	0.00477	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00467	0.00467	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00462	0.00462	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00446	0.00446	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00438	0.00438	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.0043	0.0043	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.0042	0.0042	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00418	0.00418	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00416	0.00416	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00409	0.00409	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00409	0.00409	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00404	0.00404	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00401	0.00401	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.0039	0.0039	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00386	0.00386	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00379	0.00379	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00378	0.00378	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00376	0.00376	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00372	0.00372	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00367	0.00367	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00352	0.00352	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00348	0.00348	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00344	0.00344	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00342	0.00342	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00334	0.00334	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00331	0.00331	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00308	0.00308	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.003	0.003	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00299	0.00299	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00298	0.00298	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00293	0.00293	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00293	0.00293	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00289	0.00289	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00287	0.00287	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00284	0.00284	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00279	0.00279	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00271	0.00271	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00269	0.00269	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00266	0.00266	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00264	0.00264	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00263	0.00263	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00248	0.00248	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00245	0.00245	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00239	0.00239	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00232	0.00232	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00231	0.00231	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00223	0.00223	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00219	0.00219	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00217	0.00217	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00206	0.00206	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00205	0.00205	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00204	0.00204	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00203	0.00203	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00202	0.00202	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00189	0.00189	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00188	0.00188	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00187	0.00187	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00186	0.00186	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00177	0.00177	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00171	0.00171	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00165	0.00165	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.0016	0.0016	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00157	0.00157	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00155	0.00155	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00145	0.00145	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00141	0.00141	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00124	0.00124	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00123	0.00123	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00122	0.00122	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00101	0.00101	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000844	0.000844	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000769	0.000769	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000749	0.000749	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000582	0.000582	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000582	0.000582	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000573	0.000573	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000536	0.000536	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000533	0.000533	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000531	0.000531	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000531	0.000531	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000522	0.000522	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000507	0.000507	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000486	0.000486	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000466	0.000466	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000443	0.000443	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000425	0.000425	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000404	0.000404	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	0.000353	0.000353	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00035	0.00035	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00035	0.00035	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00035	0.00035	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000345	0.000345	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00034	0.00034	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000322	0.000322	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00032	0.00032	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000319	0.000319	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00031	0.00031	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00028	0.00028	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000267	0.000267	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000212	0.000212	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000211	0.000211	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	0.000151	0.000151	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	0.000138	0.000138	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	9.1e-05	9.1e-05	CbGpPWpGaD
